| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the … F Van Leth, P Phanuphak, K Ruxrungtham, E Baraldi, S Miller, B Gazzard, ... The Lancet 363 (9417), 1253-1263, 2004 | 884 | 2004 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? E Fontas, F Van Leth, CA Sabin, N Friis-Møller, M Rickenbach, ... Journal of Infectious Diseases 189 (6), 1056-1074, 2004 | 428 | 2004 |
| Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement C Lange, I Abubakar, JWC Alffenaar, G Bothamley, JA Caminero, ... European Respiratory Journal 44 (1), 23-63, 2014 | 424 | 2014 |
| Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 F Van Leth, P Phanuphak, E Stroes, B Gazzard, P Cahn, F Raffi, R Wood, ... PLoS medicine 1 (1), e19, 2004 | 339 | 2004 |
| Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile M van der Valk, JJP Kastelein, RL Murphy, F van Leth, C Katlama, ... Aids 15 (18), 2407-2414, 2001 | 326 | 2001 |
| Risk assessment of tuberculosis in immunocompromised patients. A TBNET study M Sester, F Van Leth, J Bruchfeld, D Bumbacea, DM Cirillo, AG Dilektasli, ... American journal of respiratory and critical care medicine 190 (10), 1168-1176, 2014 | 272 | 2014 |
| Measuring tuberculosis burden, trends, and the impact of control programmes C Dye, A Bassili, AL Bierrenbach, JF Broekmans, VK Chadha, P Glaziou, ... The Lancet infectious diseases 8 (4), 233-243, 2008 | 269 | 2008 |
| A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients R Van Leeuwen, C Katlama, RL Murphy, K Squires, J Gatell, A Horban, ... Aids 17 (7), 987-999, 2003 | 265 | 2003 |
| The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART F Van Leth, S Andrews, B Grinsztejn, E Wilkins, MK Lazanas, JMA Lange, ... Aids 19 (5), 463-471, 2005 | 215 | 2005 |
| Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review SJ Leopold, F van Leth, H Tarekegn, C Schultsz Journal of Antimicrobial Chemotherapy 69 (9), 2337-2353, 2014 | 210 | 2014 |
| Are adverse events of nevirapine and efavirenz related to plasma concentrations BS Kappelhoff, F van Leth, PA Robinson, TR MacGregor, E Baraldi, ... Antivir Ther 10 (4), 489-98, 2005 | 208* | 2005 |
| Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule F van Leth, MJ Van der Werf, MW Borgdorff Bulletin of the World Health Organization 86 (1), 20-26, 2008 | 155 | 2008 |
| Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study 2NN study group Antiviral therapy 10 (1), 145-155, 2005 | 141 | 2005 |
| Multidrug-Resistant Tuberculosis in Europe, 2010–2011 G Günther, F van Leth, S Alexandru, N Altet, K Avsar, D Bang, R Barbuta, ... Emerging infectious diseases 21 (3), 409, 2015 | 114 | 2015 |
| National anti-tuberculosis drug resistance study in Tanzania TM Chonde, D Basra, SGM Mfinanga, N Range, F Lwilla, RP Shirima, ... The International Journal of Tuberculosis and Lung Disease 14 (8), 967-972, 2010 | 102 | 2010 |
| Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy FV Leth, BS Kappelhoff, D Johnson, MH Losso, A Boron-Kaczmarska, ... AIDS Research & Human Retroviruses 22 (3), 232-239, 2006 | 98 | 2006 |
| Treatment Outcomes in Multidrug-Resistant Tuberculosis G Günther, C Lange, S Alexandru, N Altet, K Avsar, D Bang, R Barbuta, ... New England Journal of Medicine 375 (11), 1103-1105, 2016 | 95 | 2016 |
| Management of patients with multidrug-resistant tuberculosis C Lange, RE Aarnoutse, JWC Alffenaar, G Bothamley, F Brinkmann, ... The International Journal of Tuberculosis and Lung Disease 23 (6), 645-662, 2019 | 83 | 2019 |
| Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe C Lange, R Duarte, M Fréchet-Jachym, G Guenther, L Guglielmetti, ... American journal of respiratory and critical care medicine 194 (8), 1029-1031, 2016 | 83 | 2016 |
| Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy W Worodria, M Massinga-Loembe, D Mazakpwe, K Luzinda, J Menten, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (1), 32-37, 2011 | 81 | 2011 |
